Trials / Completed
CompletedNCT00348348
A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,161 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Besifloxacin | Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days |
| DRUG | Moxifloxacin solution | Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days. |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2006-07-04
- Last updated
- 2015-03-24
- Results posted
- 2009-08-13
Source: ClinicalTrials.gov record NCT00348348. Inclusion in this directory is not an endorsement.